Muscle Imaging in idiopathic inflammatory myopathies

Date 22 January 2021

Location: Virtual Zoom Meeting

Title: Muscle Imaging in idiopathic inflammatory myopathies

Date: 15 - 16/ 22 January 2021

Organisers: Prof. Marianne de Visser (The Netherlands), Prof. Jiri Vencovsky (Czech Republic), Prof. Pierre G. Carlier (France)

Participants: Yves Allenbach (France), Louise Diederichsen (Denmark), Georges Demonceau (Belgique), Anneke van der Kooi (The Netherlands), Pedro Machado (UK), Andrew Mammen (USA), Harmen Reyngoudt (France), Jasper Morrow (UK), Nicolo Pipitone (Italy), Lisa Rider (USA), Jens Schmidt (Germany), Werner Stenzel (Germany), Georgio Tasca (Italy), Camiel Verhamme (The Netherlands), Jemima Albayda (USA), Michal Rataj (Poland) and Ingrid de Groot (The Netherlands) both patient representatives, Corinna Preusse (Germany) and Katerina Kubinova (Czech Republic) both participants in the Early-Career Programme

Translation of this report:

Dutch translation by Ingrid de Groot
German translation by Ruediger Schlagowski, Prof. Werner Stenzel
Polish translation by Michał Rataj

The 255th ENMC workshop on Muscle Imaging in Idiopathic Inflammatory myopathies was originally scheduled for 2020, but due to COVID-19 worldwide pandemic situation, the workshop was postponed and finally divided into two sessions: first part (virtual) in January and the second to be held in The Netherlands during fall 2021.

Idiopathic inflammatory myopathies (IIM’s) can be subdivided in different categories: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome, which is in fact an overlap syndrome, and inclusion body myositis. Previous ENMC workshops have focused on consensus on diagnosis and management of DM and IMNM.

Muscle imaging plays an important role in the diagnostic process in IIM’s and might also be helpful for monitoring disease progression which serves natural history studies and clinical trials. Despite the advantage of visualization of large muscle volume, its capability to differentiate active inflammation from chronic damage, there is still no generally accepted recommendation for the performance and evaluation of the imaging modalities.

The organizers of the meeting invited approximately 20 experts in different medical disciplines and two patients’ representatives from France, Denmark, Belgique, The Netherlands, UK, Germany, Italy, Poland, Czech Republic and USA, aiming to define recommendations concerning main technical parameters and propose a universally applicable evaluation system.

The meeting started with sharing the expected deliverables and main goals of the meeting. In particular, it was emphasized (with respect to individual technical capabilities of different workplaces), that the resulting protocol should rather be a set of good options that could be widely followed.  Subsequently, an overview on the current classification of IIMs including the clinical presentation and diagnostic criteria was given, followed by an overview of published qualitative and quantitative magnetic resonance imaging (MRI) protocols, which allow for detection inflammation (disease activity) or atrophy (loss of muscle tissue) and fatty replacement (chronic damage). Finally, in this general session, a review of established scoring systems showed how significantly the individual scoring methodologies differ across published studies.

The second day opened with presentations of the two patient representatives, emphasizing the close association of the ENMC with patients and patient organizations and the needs of patients with respect to muscle imaging. Both patients expressed their wish that muscle imaging turns out to be a reliable outcome instrument, its potential being enormous since it is non-invasive, painless and widely available.

The next talks focussed on different myositis subtypes and their patterns on MRI or other imaging modalities, e.g. in patients with IMNM fatty replacement is seen early and edema is widespread, pattern of involvement is not so characteristic, while pattern recognition in inclusion body myositis (IBM) patients is already used. Additionally, the importance of visualization in juvenile DM was underscored showing that inflammation is much more widespread as compared with the clinical findings. Another focus was on MRI as a biomarker to be used for monitoring of progression or in clinical trials. The preferential use of quantitative imaging methods including the technical difficulties was also discussed. The session was closed with a talk about the usefulness and the limitations of DEXA*, which might be a supplementary imaging method detecting lean body mass in addition to bone density.

The third day focused on other imaging modalities and correlation of imaging and other assessment methods of muscle involvement, such as muscle strength and muscle function in adults and children and pathological findings in a muscle biopsy. Novel applications of MRI bring additive useful information about muscle condition and the course of IIM, but their exact role is yet to be determined. Use of PET (positron emission tomography) and SPECT (single-photon emission computerized tomography) – both methods use a radioactive drug (tracer) to show the activity of tissues and organs within the body - for the diagnosis of myositis is rather limited, but both methods offer the advantage of also detecting malignancy, risk of which is increased in IIM’s. Ultrasound is a promising method especially in patients with IBM, where involvement of the m. flexor digitorum profundus (a forearm muscle) can be helpful for the diagnosis.

The third day ended with two talks about imaging of dysphagia (difficulty swallowing) and cardiac and lung involvement which are frequent complications in IIM’s. Impressive pictures of dysphagia on real time MRI were shown. Moreover, this not yet routinely used method is capable of detecting weakness of the diaphragm, responsible for dyspnoea (shortness of breath) in many IIM patients. Cardiac MRI has already been used in clinical practice, although the examination remains difficult to access, and the clinical implications are as yet not clearly defined.

The first virtual part of the workshop finished with a discussion about the next steps and it was decided that the workshop deliverables will be sorted into rated options. The meeting was experienced as a lively and productive workshop, leading to many discussions in both the chat and during Q&A sessions after presentations, to challenging questions and new ideas.

A final report and recommendations will follow after a next workshop scheduled for October 2021. A full report will also be published after the final meeting in Neuromuscular Disorders.

*dual energy absorptiometry (DEXA) an imaging technique that uses two low-dose x-ray beams with different levels of energy to produce a detailed image of body components; used primarily to measure bone mineral density.